CD8A and neoplasm: Anti-PD-1 mAb treatment is evaluated in patients to stimulate activation of tumor reactive T cells, however it also stimulates PD1+ CD4+ and CD8+ Tregs resulting in higher Treg suppressive activity and unwanted progression of cancer [35].